MD Anderson In Line for Big Payment to License CAR T Cell Therapy

MD Anderson Cancer Center is in line to receive $100 million in publicly traded stock as part of a licensing agreement that involves one of the most exciting emergent treatment avenues in oncology.

Both biotech company Intrexon and partner ZIOPHARM Oncology will pay MD Anderson $50 million apiece for the rights to license technology discovered at the University of Minnesota and then developed for human use at MD Anderson. The technology is a form of immunotherapy known as CAR T cell therapy; it involves customizing T cells to find and kill cancer cells.

MD Anderson President Is Encouraged By Agreement

"Genetically engineering our patients' immune-system T cells to efficiently attack and destroy cancer cells represents one of the most exciting approaches with curative potential in oncology today," said MD Anderson President Dr. Ron DePinho. "We believe coupling MD Anderson's unique CAR T cell approach with the powerful technologies of ZIOPHARM and Intrexon will allow us to build T cells that hit cancer harder, with greater precision, under tighter control and with potentially fewer side effects for patients."

In CAR T cell therapy, doctors remove a patient's T cells, implant a gene in them and infuse them back into the patient. The genetically engineered T cells are then awakened to go after the cancer.

Source: MD Anderson

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap